Company profile
HeartSciences Inc.
NASDAQ: HSCS · Healthcare · Medical - Devices
#1144 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 19GM —SS 29
v0.1 · 25/100 weight · pillars only
↑ Piotroski F, market scale · ↓ return on equity, operating margin
Methodology →Revenue TTM
$89.5M
Rev growth YoY (TTM)
+2057302.3%
Net income (FY)
-$8.8M
Employees
14
as of 2026-08-23
Market cap
$6.0M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.3k$4.3k2025
Net income-$8.8M-$8.8M2025
Operating income-$8.4M-$8.4M2025
Total assets$4.2M$4.2M2025
Liabilities$4.0M$4.0M2025
Equity$205.2k$205.2k2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is HeartSciences Inc.’s revenue?
HeartSciences Inc. booked $4.3k in FY2025 revenue, contracting 77% year over year — slower than 87% of Healthcare companies we track, at a -201499.5% net margin.
Peers · Healthcare
Alaunos Therapeutics, Inc.33DOne World Products, Inc.——Pharmagen, Inc.——Caring Brands, Inc.22DBiora Therapeutics, Inc.——Aditxt, Inc.17DNeighbors
Tarrant →Key facts
CEOAndrew Simpson
SectorHealthcare
IndustryMedical - Devices
HeadquartersSouthlake, TX
ExchangeNASDAQ: HSCS
Employees14
IPO date2022-06-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.